Clinical Trial Update: AZD6738 First Time in Patient Multiple Ascending Dose Study [Phase 1]

View source ↗

Summary

AZD6738 (berzosertib) was studied in a first-in-patient, multiple ascending-dose Phase 1 trial in relapsed/refractory hematologic cancers including chronic lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia

Drugs mentioned

• AZD6738 (ceralasertib)

Snippet

Sponsor: AstraZeneca | Conditions: 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL) | Phase 1 | Status: COMPLETED